Hang Seng Indexes Company has launched the Hang Seng Hong Kong-Listed Biotech Index, the Hang Seng Large-Mid Cap Momentum 50 Index, the Hang Seng Large-Mid Cap Momentum Tilt Index and the Hang Seng Stock Connect Hong Kong Composite Index.
The Hang Seng Hong Kong-Listed Biotech Index reflects the overall performance of biotech companies that are listed in Hong Kong, including stocks listed through the Listing Rules Chapter 18A of Stock Exchange of Hong Kong and stocks classified as ‘Biotechnology’, ‘Pharmaceuticals’ or ‘Medical Devices’ under the Hang Seng Industry Classification System. With growing interest in biotech companies among investors, this new index provides an indicator of the market performance of the sector.
The Hang Seng Large-Mid Cap Momentum 50 Index and the Hang Seng Large-Mid Cap Momentum Tilt Index use ‘momentum factor’ strategies that aim to capture returns when high-momentum companies maintain high-price performances. By offering momentum factor as a new benchmark for tracking performance, the launch of these two indexes further enriches Hang Seng Indexes’ suite of Factor & Strategy indexes category.
The Hang Seng Stock Connect Hong Kong Composite Index is a comprehensive benchmark for monitoring the performance of all stocks that are eligible for Southbound Trading under the Stock Connect scheme.
The four new indexes are calculated and disseminated in real-time at two-second intervals. More details about the new indexes are provided in the appendices that accompany this release.
